FDA grants fast track to Clovis Oncology

The Food and Drug Administration granted accelerated approval for Clovis Oncology Inc.'s (Nasdaq: CLVS) new drug application for rucaparib sending the stock price soaring $4.93 to close at $23.03.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.